Recent research has demonstrated that inhibition of intestinal FXR signaling can improve metabolic disorders by increasing hepatic bile acid pool, reducing cholesterol accumulation, and alleviating fatty liver (147). Here, NR1H4 is linked to Other metabolic disease.